Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Danyelza

(dan-YEL-zah)

A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children aged 1 year and older and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Danyelza binds to a substance called GD2, which is found on some types of cancer cells. Danyelza may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called naxitamab.

Danyelza

Search NCI's Dictionary of Cancer Terms